HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer.

AbstractOBJECTIVE:
Cisplatin-based chemotherapy has been shown to improve survival in cervical cancer; however, treatment is associated with tumor resistance and significant toxicity. Lipoplatin is a new liposomal formulation of cisplatin, developed to reduce cisplatin toxicity, to improve drug accumulation at tumor sites and to overcome drug resistance. The aim of this study is to analyze the antitumoral activity of lipoplatin against cisplatin-resistant cervical cancer cells and to investigate its mechanism of action.
METHODS:
The activity and mechanism of action of lipoplatin were studied in the ME-180 cervical cancer cell line and its cisplatin-resistant clone R-ME-180 and HeLa cells using cell proliferation assays, flow cytometry, ELISA assay, cell migration, spheroids and tumor xenograft.
RESULTS:
We demonstrated that lipoplatin exhibited a potent antitumoral activity on HeLa, ME-180 cells and its cisplatin-resistant clone R-ME-180. Lipoplatin inhibited cell proliferation in a dose-dependent manner and was more active than the reference drug cisplatin in R-ME-180 cells and induced apoptosis, as evaluated by Annexin-V staining and DNA fragmentation, caspases 9 and 3 activation, Bcl-2, and Bcl-xL down-regulation, but Bax up-regulation inhibited thioredoxin reductase (TrxR) enzymatic activity and increased reactive oxygen species (ROS) accumulation; reduced EGFR expression and inhibited both migration and invasion. R-ME-180, but not ME-180 cells, generated three-dimensional (3D)-multicellular spheroids expressing the cancer stem cell marker ALDH. The ability of R-ME-180 cells to form spheroids in vitro and tumors in nude mice was also remarkably decreased by lipoplatin.
CONCLUSIONS:
Overall, our results suggest that lipoplatin has potential for the treatment of cisplatin-resistant cervical cancer.
AuthorsNaike Casagrande, Monica De Paoli, Marta Celegato, Cinzia Borghese, Maurizio Mongiat, Alfonso Colombatti, Donatella Aldinucci
JournalGynecologic oncology (Gynecol Oncol) Vol. 131 Issue 3 Pg. 744-52 (Dec 2013) ISSN: 1095-6859 [Electronic] United States
PMID24029417 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2013.
Chemical References
  • Liposomes
  • Reactive Oxygen Species
  • lipoplatin
  • Aldehyde Dehydrogenase
  • Thioredoxin-Disulfide Reductase
  • ErbB Receptors
  • Cisplatin
Topics
  • Aldehyde Dehydrogenase (metabolism)
  • Animals
  • Apoptosis (drug effects)
  • Cell Growth Processes (drug effects)
  • Cell Line, Tumor
  • Cell Movement (drug effects)
  • Cisplatin (administration & dosage, pharmacology)
  • Drug Resistance, Neoplasm
  • ErbB Receptors (biosynthesis)
  • Female
  • HeLa Cells
  • Humans
  • Liposomes (administration & dosage)
  • Mice
  • Mice, Nude
  • Mitochondria (drug effects, metabolism)
  • Neoplastic Stem Cells (drug effects, pathology)
  • Reactive Oxygen Species (metabolism)
  • Spheroids, Cellular
  • Thioredoxin-Disulfide Reductase (antagonists & inhibitors, metabolism)
  • Uterine Cervical Neoplasms (drug therapy, metabolism, pathology)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: